Johnson & Johnson (JNJ) 96.87 $JNJ
3 Predictions for the New Week
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 2:00PM CDT
I went out on a limb last week , and now it's time to see how that decision played out. I predicted that Sirius XM Radio would move higher on the week. The satellite radio provider had slipped in recent weeks, and I figured it was due for...
Got Allergies? FDA to the Rescue
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 12, 9:00AM CDT
Fresh-cut grass is Kryptonite to allergy sufferers, but a new pill from French drug company Stallergenes may get millions of weekend warriors back outdoors this summer. The FDA's approval of Stallergenes' grass-allergy pill, Oralair, offers a...
Why Rambus, Allergan, and JAKKS Pacific Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 11, 7:05PM CDT
Friday didn't turn out to be quite as bad a day for the stock market as Thursday was, with major-market benchmarks ending the day down around 1% to 1.5% instead of the up to 3% losses that we saw yesterday. Nevertheless, continued weakness in some...
Final Glance: Pharmaceuticals companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Abbott Labs Progresses with Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:40PM CDT
Abbott Laboratories (ABT) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS).
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:15PM CDT
Gilead announced encouraging results from two phase II studies and a compassionate access study on Sovaldi.
Balanced Risk-Reward for The Cooper Companies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:00PM CDT
We believe The Cooper Companies is poised for growth given its significant market share in high growth specialty lenses.
What's Behind Intuitive Surgical Inc's Revenue Miss?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Apr 11, 1:30PM CDT
If surgical robot pioneer Intuitive Surgical is going to keep its heady med-tech growth stock multiple, it has to do better than this. After logging just 4% revenue growth in 2013, Intuitive's announcement of a 24% drop to start 2014...
Business events scheduled for the coming week
By The Associated Press - AP - Fri Apr 11, 1:01PM CDT
MONDAY, April 14
Midday Glance: Pharmaceuticals companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Global Infusion Pumps & Accessories (Volumetric, Syringe, Enteral, Insulin, Implantable, PCA Pump) Market 2014-2018
M2 - Fri Apr 11, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6xwqb/infusion_pumps) has announced the addition of the "Infusion Pumps & Accessories Market by Product, Application & by End-user - Global Forecasts to 2018" report to their offering. The infusion pumps market is expected to grow at a moderate CAGR from 2013 to 2018 due to factors such as increasing chronic diseases, rising applications of infusion products in home care, and favorable reimbursement coverage for the use of infusion products. Despite of these growth factors, the increasing errors with use of infusion pumps and rising pressures to meet with stringent regulatory requirements may hamper the growth of this market to a certain extent. The global market is segmented on the basis of product types, applications, end users, and geographies. Based on the type of product, the market is further segmented into devices (pumps) and accessories/disposables. The accessories/disposables are further segmented into dedicated disposables and non-dedicated disposables. Depending on the application area, the market is classified into diabetes, chemotherapy/oncology, gastroenterology, hematology, analgesia/pain management, pediatrics/neonatology, and others. Based on end users, the market is categorized into hospitals, home care, and others. The overall market is further divided into four major geographies, namely North America, Europe, Asia-Pacific, and the Rest of the World (RoW). These regions are further analyzed at the country level. In 2013, the volumetric infusion pumps segment commanded the largest share of the global market and is expected to grow with moderate CAGR in next five years. The increasing applications and acceptance of insulin infusion pumps, patient controlled analgesia pumps, and implantable infusion pumps is expected to push the growth of these segments at a strong CAGR during the forecast period of 2013 to 2018. North America dominated the infusion pumps market in 2013, accounting for a share of around 40% to 45%. However, the developed geographies like North America and Europe are likely to grow at lower CAGRs than the Asia-Pacific and RoW markets. The growing economical condition, increasing healthcare expenditures, and rising adoption of newer technologies in the Asia-Pacific region will drive the market in this region. Scope Product - Volumetric - Syringe - Enteral - Insulin - Implantable - PCA Pump Application - Diabetes - Chemotherapy - Nutrition - Pain Management Key Topics Covered: - Introduction - Executive Summary - Premium Insight - Market Dynamics - Infusion Pumps & Accessories Market, By Product - Infusion Pumps And Accessories Market, By Application - Infusion Pumps And Accessories Market, By End User - Geographic Analysis - Competitive Landscape - Company Profiles - B. Braun Melsungen Ag - Baxter International Inc. - Carefusion Corporation - Fresenius Se & Co. Kgaa - ospira, Inc. - Johnson & Johnson - Medtronic, Inc. - Moog Inc. - Smiths Medical - Terumo Corporation Visit http://www.researchandmarkets.com/research/n6...sion_pumps
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
global Traditional Wound Management Market Overview 2013-2019 - Cost Sensitivity Spurs Adoption in Emerging Markets
M2 - Fri Apr 11, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6gfptm/traditional_wound) has announced the addition of the "global Traditional Wound Management Market Overview 2013-2019 - Cost Sensitivity Spurs Adoption in Emerging Markets" report to their offering. Traditional Wound Management Market is Forecast to Reach $1.9 Billion by 2019 Global Traditional Wound Management Market Overview 2013-2019 looks at the market, key market players, and market dynamics for the global traditional wound management market. It provides a synopsis of the various factors influencing the market and its segments - bandages, gauzes and sponges. The global market for traditional wound management was valued at $1.6 billion in 2012, and is forecast to reach $1.9 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 2.1%. Future growth of traditional wound management is expected to be subdued, due to increasing preference for advanced wound management techniques, particularly in developed economies such as the US and Europe. Given that traditional wound management is still widely perceived to be a cost-effective alternative to advanced therapies, the latter is actually proving to be significantly economical in terms of overall treatment costs. The report also gives company descriptions, lists the key marketed products for major market players and details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by a team of industry experts. Scope - Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil - Information on market size for the three traditional wound management market segments: bandages, gauzes and sponges - Annualized market-revenue data forecast to 2019, and company share data for 2012 - Information on the leading technologies of key players: Paul Hartmann, J&J, Covidien, B. Braun, Cremer, Molnlycke, Synergy Health and Hollister. Key Topics Covered: - Tables & Figures - Introduction - Global Traditional Wound Management Market, Device Overview - Global Traditional Wound Management Market, Market Characterization - Global Traditional Wound Management Market, Country-Specific Revenue (2005-2019) - Global Traditional Wound Management Market, Reimbursement Systems - Global Traditional Wound Management Market, Distribution Systems - Global Traditional Wound Management Market, Company Profiles - Global Traditional Wound Management Market, Consolidation Landscape - Appendix Companies Mentioned - B. Braun Melsungen AG - Covidien plc - Cremer SA - Hollister Incorporated - Johnson & Johnson - M?lnlycke Health Care AB - Paul Hartmann AG - Synergy Health plc For more information visit http://www.researchandmarkets.com/research/6g...onal_wound
A Make or Break Week for Q1 Earnings Season - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 11, 1:43AM CDT
A Make or Break Week for Q1 Earnings Season - Earnings Preview
ADP's
at Investor's Business Daily - Thu Apr 10, 5:48PM CDT
ADP's (ADP) credit rating was downgraded to AA by S&P on its dealer unit spinoff plan. The only U.S. companies with a AAA rating are Exxon Mobil (XOM), Johnson & Johnson (JNJ) and Microsoft (MSFT).
3 Predictions for the New Week
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 2:00PM CDT
I went out on a limb last week , and now it's time to see how that decision played out. I predicted that Sirius XM Radio would move higher on the week. The satellite radio provider had slipped in recent weeks, and I figured it was due for...
Got Allergies? FDA to the Rescue
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 12, 9:00AM CDT
Fresh-cut grass is Kryptonite to allergy sufferers, but a new pill from French drug company Stallergenes may get millions of weekend warriors back outdoors this summer. The FDA's approval of Stallergenes' grass-allergy pill, Oralair, offers a...
Why Rambus, Allergan, and JAKKS Pacific Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 11, 7:05PM CDT
Friday didn't turn out to be quite as bad a day for the stock market as Thursday was, with major-market benchmarks ending the day down around 1% to 1.5% instead of the up to 3% losses that we saw yesterday. Nevertheless, continued weakness in some...
Final Glance: Pharmaceuticals companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Abbott Labs Progresses with Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:40PM CDT
Abbott Laboratories (ABT) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS).
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:15PM CDT
Gilead announced encouraging results from two phase II studies and a compassionate access study on Sovaldi.
Balanced Risk-Reward for The Cooper Companies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:00PM CDT
We believe The Cooper Companies is poised for growth given its significant market share in high growth specialty lenses.
What's Behind Intuitive Surgical Inc's Revenue Miss?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Apr 11, 1:30PM CDT
If surgical robot pioneer Intuitive Surgical is going to keep its heady med-tech growth stock multiple, it has to do better than this. After logging just 4% revenue growth in 2013, Intuitive's announcement of a 24% drop to start 2014...
Business events scheduled for the coming week
By The Associated Press - AP - Fri Apr 11, 1:01PM CDT
MONDAY, April 14
Midday Glance: Pharmaceuticals companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Global Infusion Pumps & Accessories (Volumetric, Syringe, Enteral, Insulin, Implantable, PCA Pump) Market 2014-2018
M2 - Fri Apr 11, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6xwqb/infusion_pumps) has announced the addition of the "Infusion Pumps & Accessories Market by Product, Application & by End-user - Global Forecasts to 2018" report to their offering. The infusion pumps market is expected to grow at a moderate CAGR from 2013 to 2018 due to factors such as increasing chronic diseases, rising applications of infusion products in home care, and favorable reimbursement coverage for the use of infusion products. Despite of these growth factors, the increasing errors with use of infusion pumps and rising pressures to meet with stringent regulatory requirements may hamper the growth of this market to a certain extent. The global market is segmented on the basis of product types, applications, end users, and geographies. Based on the type of product, the market is further segmented into devices (pumps) and accessories/disposables. The accessories/disposables are further segmented into dedicated disposables and non-dedicated disposables. Depending on the application area, the market is classified into diabetes, chemotherapy/oncology, gastroenterology, hematology, analgesia/pain management, pediatrics/neonatology, and others. Based on end users, the market is categorized into hospitals, home care, and others. The overall market is further divided into four major geographies, namely North America, Europe, Asia-Pacific, and the Rest of the World (RoW). These regions are further analyzed at the country level. In 2013, the volumetric infusion pumps segment commanded the largest share of the global market and is expected to grow with moderate CAGR in next five years. The increasing applications and acceptance of insulin infusion pumps, patient controlled analgesia pumps, and implantable infusion pumps is expected to push the growth of these segments at a strong CAGR during the forecast period of 2013 to 2018. North America dominated the infusion pumps market in 2013, accounting for a share of around 40% to 45%. However, the developed geographies like North America and Europe are likely to grow at lower CAGRs than the Asia-Pacific and RoW markets. The growing economical condition, increasing healthcare expenditures, and rising adoption of newer technologies in the Asia-Pacific region will drive the market in this region. Scope Product - Volumetric - Syringe - Enteral - Insulin - Implantable - PCA Pump Application - Diabetes - Chemotherapy - Nutrition - Pain Management Key Topics Covered: - Introduction - Executive Summary - Premium Insight - Market Dynamics - Infusion Pumps & Accessories Market, By Product - Infusion Pumps And Accessories Market, By Application - Infusion Pumps And Accessories Market, By End User - Geographic Analysis - Competitive Landscape - Company Profiles - B. Braun Melsungen Ag - Baxter International Inc. - Carefusion Corporation - Fresenius Se & Co. Kgaa - ospira, Inc. - Johnson & Johnson - Medtronic, Inc. - Moog Inc. - Smiths Medical - Terumo Corporation Visit http://www.researchandmarkets.com/research/n6...sion_pumps
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
global Traditional Wound Management Market Overview 2013-2019 - Cost Sensitivity Spurs Adoption in Emerging Markets
M2 - Fri Apr 11, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6gfptm/traditional_wound) has announced the addition of the "global Traditional Wound Management Market Overview 2013-2019 - Cost Sensitivity Spurs Adoption in Emerging Markets" report to their offering. Traditional Wound Management Market is Forecast to Reach $1.9 Billion by 2019 Global Traditional Wound Management Market Overview 2013-2019 looks at the market, key market players, and market dynamics for the global traditional wound management market. It provides a synopsis of the various factors influencing the market and its segments - bandages, gauzes and sponges. The global market for traditional wound management was valued at $1.6 billion in 2012, and is forecast to reach $1.9 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 2.1%. Future growth of traditional wound management is expected to be subdued, due to increasing preference for advanced wound management techniques, particularly in developed economies such as the US and Europe. Given that traditional wound management is still widely perceived to be a cost-effective alternative to advanced therapies, the latter is actually proving to be significantly economical in terms of overall treatment costs. The report also gives company descriptions, lists the key marketed products for major market players and details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by a team of industry experts. Scope - Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil - Information on market size for the three traditional wound management market segments: bandages, gauzes and sponges - Annualized market-revenue data forecast to 2019, and company share data for 2012 - Information on the leading technologies of key players: Paul Hartmann, J&J, Covidien, B. Braun, Cremer, Molnlycke, Synergy Health and Hollister. Key Topics Covered: - Tables & Figures - Introduction - Global Traditional Wound Management Market, Device Overview - Global Traditional Wound Management Market, Market Characterization - Global Traditional Wound Management Market, Country-Specific Revenue (2005-2019) - Global Traditional Wound Management Market, Reimbursement Systems - Global Traditional Wound Management Market, Distribution Systems - Global Traditional Wound Management Market, Company Profiles - Global Traditional Wound Management Market, Consolidation Landscape - Appendix Companies Mentioned - B. Braun Melsungen AG - Covidien plc - Cremer SA - Hollister Incorporated - Johnson & Johnson - M?lnlycke Health Care AB - Paul Hartmann AG - Synergy Health plc For more information visit http://www.researchandmarkets.com/research/6g...onal_wound
A Make or Break Week for Q1 Earnings Season - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 11, 1:43AM CDT
A Make or Break Week for Q1 Earnings Season - Earnings Preview
ADP's
at Investor's Business Daily - Thu Apr 10, 5:48PM CDT
ADP's (ADP) credit rating was downgraded to AA by S&P on its dealer unit spinoff plan. The only U.S. companies with a AAA rating are Exxon Mobil (XOM), Johnson & Johnson (JNJ) and Microsoft (MSFT).
